(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 179.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Roivant Sciences's revenue in 2025 is $29,053,000.On average, 4 Wall Street analysts forecast ROIV's revenue for 2026 to be $19,394,867,177, with the lowest ROIV revenue forecast at $4,840,219,218, and the highest ROIV revenue forecast at $40,788,364,200. On average, 4 Wall Street analysts forecast ROIV's revenue for 2027 to be $33,356,044,437, with the lowest ROIV revenue forecast at $16,315,345,680, and the highest ROIV revenue forecast at $76,138,279,840.
In 2028, ROIV is forecast to generate $582,362,667,926 in revenue, with the lowest revenue forecast at $356,898,186,750 and the highest revenue forecast at $807,827,149,102.